Phase
Condition
Pulmonary Arterial Hypertension
Treatment
Usual Care
mHealth Intervention
Clinical Study ID
Ages 13-19 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Adolescents between ages 13-19 years.
Diagnosed with idiopathic, heritable, or associated (connective tissue disease,drugs, or toxins) pulmonary arterial hypertension (PAH), or PAH due to simplecongenital heart disease (i.e. atrial septal defect).
WHO functional class I-III
Stable PAH-specific medication regimen for three months prior to enrollment.Subjects with only a single diuretic adjustment in the prior three months will beincluded. Adjustments in IV prostacyclin for side effect management are allowed.
Forced vital capacity >65% predicted with no or minimal interstitial lung diseasebased on reviews of imaging studies by PI and medical monitor.
Exclusion
Exclusion Criteria:
Prohibited from normal activity due to wheelchair bound status, bed bound status,reliance on a cane/walker, activity-limiting angina, activity-limitingosteoarthritis, or other condition that limits activity.
Pregnancy
Diagnosis of PAH etiology other than idiopathic, heritable, or associated.
Functional class IV heart failure
Requirement of > 2 diuretic adjustment in the prior three months.
Preferred form of activity is not measured by an activity tracker (swimming, yoga,ice skating, stair master, or activities on wheels such as bicycling orrollerblading).
Involved in any other investigational intervention.
Study Design
Connect with a study center
Vanderbilt University Medical Center
Nashville, Tennessee 37232
United StatesActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.